Filing Details
- Accession Number:
- 0001209191-18-051069
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-09-14 16:12:49
- Reporting Period:
- 2018-09-12
- Accepted Time:
- 2018-09-14 16:12:49
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 850261 | Sorrento Therapeutics Inc. | SRNE | Services-Commercial Physical & Biological Research (8731) | 330344842 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1609313 | Ally Bridge Group Capital Partners Ii, L.p. | Unit 3002-3004, 30Th Floor Gloucester Tower, The Landmark, Central Hong Kong K3 00000 | No | No | Yes | No | |
| 1667354 | Ltd Fund Master Healthcare Lb Bridge Ally | Unit 1602, 16/F, Wheelock House 20 Pedder Street, Central Hong Kong K3 00000 | No | No | Yes | No | |
| 1668027 | Ltd Management Abg | Unit 3002-3004, 30Th Floor Gloucester Tower, The Landmark, Central Hong Kong K3 00000 | No | No | Yes | No | |
| 1668028 | Ltd Management Lb Bridge Ally | Unit 1602, 16/F, Wheelock House 20 Pedder Street, Central Hong Kong K3 00000 | No | No | Yes | No | |
| 1668029 | Fan Yu | Unit 3002-3004, 30Th Floor Gloucester Tower, The Landmark, Central Hong Kong K3 00000 | No | No | Yes | No | |
| 1668219 | Bin Li | Unit 1602, 16/F, Wheelock House 20 Pedder Street, Central Hong Kong K3 00000 | No | No | Yes | No | |
| 1674513 | Ally Bridge Group Innovation Capital Partners Iii, L.p. | Unit 3002-3004, 30Th Floor Gloucester Tower, The Landmark, Central Hong Kong K3 00000 | No | No | Yes | No | |
| 1676083 | Ltd Srne Abg | Unit 3002-3004, 30Th Floor Gloucester Tower, The Landmark, Central Hong Kong K3 00000 | No | No | Yes | No | |
| 1676141 | Ltd Ii-So Abg | Unit 3002-3004, 30Th Floor Gloucester Tower, The Landmark, Central Hong Kong K3 00000 | No | No | Yes | No | |
| 1704525 | Ltd Innovation-So Abg | Unit 3002-3004, 30Th Floor Gloucester Tower, The Landmark, Central Hong Kong K3 00000 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2018-09-12 | 189,754 | $5.06 | 1,120,834 | No | 4 | S | Indirect | Through ABG II-SO Limited |
| Common Stock | Disposition | 2018-09-13 | 29,137 | $5.01 | 1,091,697 | No | 4 | S | Indirect | Through ABG II-SO Limited |
| Common Stock | Disposition | 2018-09-13 | 78,677 | $4.92 | 1,013,020 | No | 4 | S | Indirect | Through ABG II-SO Limited |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | Through ABG II-SO Limited |
| No | 4 | S | Indirect | Through ABG II-SO Limited |
| No | 4 | S | Indirect | Through ABG II-SO Limited |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 1,328,529 | Indirect | Through Ally Bridge LB Healthcare Master Fund Limited |
| Common Stock | 3,041,759 | Indirect | Through ABG SRNE Limited |
| Common Stock | 1,408,027 | Indirect | Through ABG Innovation-SO Limited |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Warrants | $8.50 | 2019-05-31 | 432,432 | 432,432 | Indirect | |
| Common Stock | Warrants | $8.50 | 2019-05-31 | 432,432 | 432,432 | Indirect | |
| Common Stock | Warrants | $8.50 | 2019-06-07 | 540,540 | 540,540 | Indirect |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2019-05-31 | 432,432 | 432,432 | Indirect |
| 2019-05-31 | 432,432 | 432,432 | Indirect |
| 2019-06-07 | 540,540 | 540,540 | Indirect |
Footnotes
- The Reporting Persons are making this joint, single filing because they may be deemed to constitute a "group" within the meaning of Section 13(d)(3) of the Securities Exchange Act 1934 as amended (the "Act").
- The Form 4 is filed by and on behalf of each of the following persons (each a "Reporting Person"): (i) ABG II-SO Limited ("ABG II-SO"), a British Virgin Islands limited company, (ii) Ally Bridge Group Capital Partners II, L.P., a Cayman Islands limited partnership, (iii) Ally Bridge LB Healthcare Master Fund Limited ("ABG LB"), a Cayman Islands limited company, (iv) Ally Bridge LB Management Limited, a Cayman Islands limited company, (v) ABG SRNE Limited ("ABG SRNE"), a British Virgin Islands limited company, (vi) Ally Bridge Group Innovation Capital Partners III, L.P., a Cayman Islands limited company, (vii) ABG Management Ltd., a Cayman Islands limited partnership, (viii) ABG Innovation-SO Limited, a British Virgin Islands limited company,
- (ix) Mr. Fan Yu, a director of ABG LB and a shareholder and director of Ally Bridge LB Management Limited, and the sole shareholder and director of ABG Management Ltd., and (x) Mr. Bin Li, a director and executive officer of ABG LB and a shareholder and director of Ally Bridge LB Management Limited.
- Each Reporting Person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for the purpose of Section 16 of the Act or otherwise, the beneficial owner of any securities covered by this statement. Each Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.
- ABG II-SO directly owns 1,013,020 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge Group Capital Partners II, L.P., as parent of ABG II-SO, (ii) ABG Management Ltd., as manager of Ally Bridge Group Capital Partners II, L.P., and (iii) Mr. Fan Yu, as sole shareholder and director of ABG Management Ltd.
- ABG LB directly owns (i) 1,328,529 shares of common stock of the Issuer and (ii) warrants to purchase 432,432 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge LB Management Limited, as manager of ABG LB, (ii) Mr. Fan Yu, as a shareholder and director of Ally Bridge LB Management Limited, and (iii) Mr. Bin Li, as a shareholder and director of Ally Bridge LB Management Limited.
- ABG SRNE directly owns (i) 3,041,759 shares of common stock of the Issuer and (ii) warrants to purchase 972,972 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge Group Innovation Capital Partners III, L.P., as owner of the sole voting share of ABG SRNE, (ii) ABG Management Ltd., as manager of Ally Bridge Group Innovation Capital Partners III, L.P., and (iii) Mr. Fan Yu, as sole shareholder and director of ABG Management Ltd.
- Ally Bridge Group Innovation Capital Partners III, L.P. is the owner of the sole voting share of ABG Innovation-SO Limited, which directly owns 1,408,027 shares of common stock of the Issuer. The following Reporting Persons may be deemed to beneficially own such securities: (i) Ally Bridge Group Innovation Capital Partners III, L.P., (ii) ABG Management Ltd., as manager of Ally Bridge Group Innovation Capital Partners III, L.P., and (iii) Mr. Fan Yu, as sole shareholder and director of ABG Management Ltd.
- The warrants are exercisable at any time on or after May 31, 2016.
- The warrants are exercisable at any time on or after June 7, 2016.
Billionaire Hedge Funds
